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Intragenic copy-number variants (CNVs) contribute to the allelic spectrum of both Mendelian and complex disorders. Although path-
ogenic deletions and duplications in SPAST (mutations in which cause autosomal-dominant spastic paraplegia 4 [SPG4]) have been
described, their origins and molecular consequences remain obscure. We mapped breakpoint junctions of 54 SPAST CNVs at nucleotide
resolution. Diverse combinations of exons are deleted or duplicated, highlighting the importance of particular exons for spastin func-
tion. Of the 54 CNVs, 38 (70%) appear to be mediated by an Alu-based mechanism, suggesting that the Alu-rich genomic architecture of
SPAST renders this locus susceptible to various genome rearrangements. Analysis of breakpointAlus further informs amodel of Alu-medi-
ated CNV formation characterized by small CNV size and potential involvement ofmechanisms other than homologous recombination.
Twelve deletions (22%) overlap part of SPAST and a portion of a nearby, directly oriented gene, predicting novel chimeric genes in these
subjects’ genomes. cDNA from a subject with a SPAST final exon deletion contained multiple SPAST:SLC30A6 fusion transcripts, indi-
cating that SPAST CNVs can have transcriptional effects beyond the gene itself. SLC30A6 has been implicated in Alzheimer disease,
so these fusion gene data could explain a report of spastic paraplegia and dementia cosegregating in a family with deletion of the final
exon of SPAST. Our findings provide evidence that the Alu genomic architecture of SPAST predisposes to diverse CNValleles with distinct
transcriptional—and possibly phenotypic—consequences. Moreover, we provide further mechanistic insights into Alu-mediated copy-
number change that are extendable to other loci.Introduction
DNA copy-number variants (CNVs) deleting or duplicating
parts of genes contribute to exon shuffling and gene evolu-
tion, thus playing an important role in both Mendelian
and common/complex traits.1–4 CNVs in SPAST (2p22.3
[MIM 604277]) cause 8%–41% of autosomal-dominant
spastic paraplegia 4 (SPG4 [MIM 182601]),5–7 the predom-
inant form of hereditary spastic paraplegia (HSP).8,9 Het-
erozygous CNVs deleting (n > 70 cases) and duplicating
(n ¼ 2 cases) various SPAST exons or the entire SPAST
gene have been described.10,11 However, it is not known
how these CNVs form, whether and/or why SPAST is
particularly susceptible to these rearrangements, and
what the consequences of SPAST CNVs, either molecular
or phenotypic, are in comparison to other types of muta-
tions in the same gene.
Multiple molecular mechanisms have been described or
proposed to generate small CNVs12,13 commensurate with
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SPAST CNV formation, however, are largely absent because
of methodological limitations: CNVs in SPAST are usually
studied with multiplex ligation-dependent probe amplifi-
cation (MLPA),6 a method that reveals the copy number
of each of the 17 SPAST exons but leaves the exact location,
sequence, and characteristics of CNV boundaries (i.e.,
breakpoint junctions) unknown.
We previously ascertained the nucleotide sequence of
breakpoint junctions for three SPAST CNVs deleting the
final exon of the gene.14 Although the size and genomic
position of each deletion differed, all deletion breakpoints
localized to pairs of directly oriented Alu elements, a
repetitive DNA element of ~300 base pairs (bp) present in
>106 copies in the human genome.15 This Alu-Alu-medi-
ated rearrangement phenomenon has been reported in
studies of small, germline CNVs at other disease loci,16–20
somatic rearrangements found in malignancies,20,21 and
rearrangements arising during human evolution.22–24
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recombination, a proposed molecular mechanism in
which homologous recombination (HR) utilizes nonallelic
Alu pairs as substrates to generate CNVs.20,25 Intriguingly,
the CNVs in our small cohort exhibited features poten-
tially inconsistent with formation by ectopic homologous
recombination: one CNV was potentially complex, and
breakpoint Alu pairs shared <90% identity. The remaining
four SPAST CNVs with known breakpoints do not localize
to Alus.11,26–28 Therefore, we sought to further investigate
the mechanism(s) generating SPAST CNVs, including the
way in which the Alu-rich architecture of SPAST14 might
render this gene or particular exons within it susceptible
to CNV mutations.
SPG4, the clinical phenotype associated with SPAST
mutation, is predominately characterized by progressive
lower-limb weakness and spasticity caused by degenera-
tion of upper motor neurons in the corticospinal tract.29
Occasional reports of additional phenotypes suggestive of
CNS pathology exist,30–32 and subtle cognitive impairment
has been suggested to be a moderately penetrant feature of
the disease (reviewed by Du¨rr et al. in GeneReviews).
Furthermore, severity and age of onset can vary. No consis-
tent genotype-phenotype correlation exists for alleles in
SPAST.33 Most disease-causing variants have been thought
to represent loss-of-function alleles. However, we previ-
ously hypothesized that a subset of SPAST CNVs—those
overlapping the 30 end of the gene—might also affect
expression of SLC30A6 (MIM 611148), the nearest gene
to SPAST, located 8 kb downstream.14 SLC30A6 encodes a
zinc transporter, ZnT6. Although SLC30A6 variants have
not been found in association with any disease, zinc
transporter (including ZnT6) dynamics are altered in the
brains of some individuals with Alzheimer disease.34,35
Thus, we investigated the possibility of SPAST CNVs
dysregulating SLC30A6 expression, particularly given re-
ports of individuals with comorbid spastic paraplegia and
dementia.31,36
We studied SPAST CNVs in an additional 51 subjects and
now report diverse CNVs for which Alu-mediated forma-
tion predominates. These CNVs rearrange a variety of
exons including 24 (47%) affecting the final (30) exon of
the gene and potentially forming fusion transcripts with
or altering expression of SLC30A6 and other adjacent
genes. In cultured lymphoblastoid cells from one subject
with a SPAST exon 17 deletion, we identify multiple SPAST:
SLC30A6 fusion transcripts. Finally, we propose alternative
models to homologous recombination for Alu-mediated
CNV formation based upon the observed breakpoint fea-
tures of CNVs in SPAST; these are extendable to other
loci, potentially enabling genome-wide predictions of
Alu-mediated genome instability.
Subjects and Methods
Subjects
Subjects consisted primarily of individuals with a clinical diag-
nosis of spastic paraplegia and a previous finding of a SPAST144 The American Journal of Human Genetics 95, 143–161, August 7CNV identified during clinical laboratory screening or a family-
based research study (Table S1 available online). This study was
approved by the Institutional Review Board for Human Subjects
Research of Baylor College of Medicine (H-28128, H-25466,
H-9170, H-29697). Remaining DNA samples were deidentified
for our analyses. Subjects are further described in Tables 1 and
S1. Owing to the anonymized nature of sample acquisitions,
phenotypic details beyond a clinical diagnosis of spastic para-
plegia are unknown in most cases. Samples from Athena Diagnos-
tics were intentionally enriched for exon 17 CNVs. All other
sources contributed all available CNVs in their collections.Mapping CNV Breakpoints
DNA was extracted from whole blood using the Gentra Puregene
Blood Kit (QIAGEN) or obtained from previously archived sam-
ples. A total of 50 CNVs in SPAST were confirmed and mapped
using a custom comparative genomic hybridization (CGH) array
targeted to SPAST and flanking regions (approximately one mega-
base 50 and 30). This Agilent 8 3 15 k probe oligonucleotide array
(format ¼ G4427A; design ID ¼ 037541) was custom designed
using Agilent eArray and contains approximately one probe per
200 base pairs (bp) throughout the targeted region. Array CGH
procedures have been described.37 Hybridization controls were
gender matched unless an individual’s gender was unknown, in
which cases female DNA (HapMap individual NA15510) was
used. Array image files were processed using Agilent Feature
Extraction software (v.10) and CNVs called with Agilent Genomic
Workbench software (v.7). One CNV (Ruhr 29) was mapped using
a genome-wide Agilent 1M probe oligonucleotide CGH array
(format¼G4824A; design ID¼ 02159) because the CNVextended
beyond the boundaries of our targeted array.
CNVs were further confirmed and mapped by long-range PCR
with primers (Table S2) spanning their predicted breakpoints.
PCR reagents and concentrations have been described previ-
ously.38 The thermal cycler was programmed as follows: 94C 3
1 min; 30 cycles of 94C 3 30 s followed by 68C 3 7 min;
72C 3 10 min. Breakpoint PCR products were treated with
ExoStar (GE Healthcare) according to the manufacturer’s instruc-
tions or extracted from an agarose gel using the Zymoclean gel
DNA recovery kit (Zymo Research), also according to the manufac-
turer’s instructions, then sequenced by Sanger di-deoxynucleotide
sequencing (Lone Star Labs; SeqWright; Baylor College of Medi-
cine Sequencing Core, Houston, TX, USA).
All genomic coordinates are based on the February 2009 genome
build (GRCh37/hg19) unless otherwise specified. SPAST exon
numbering is based on UCSC transcript variant uc002roc.3 (17
exons). SLC30A6 exon numbering is based on UCSC transcript
variant uc002rof.2 (15 exons).STR Analysis
Alleles at 15 short tandem repeats (STRs) and subject gender were
assessed using the Applied Biosystems AmpFISTR Identifiler Direct
PCR Amplification Kit (Life Technologies) according to the manu-
facturer’s instructions.Haplotype Analysis
For each deletion found in multiple individuals, primer pairs
(Table S2) were designed to amplify 5–10 kb flanking each side
of the deletion. The deleted allele was selectively amplified or
was isolated based on size by gel extraction as described above.
Common SNPs (allele frequencyR 1% in dbSNP 138) within these, 2014
amplicons were genotyped by Sanger sequencing using a custom
set of sequencing primers (Table S2). To assess the frequency of
the observed haplotypes in the population, we obtained 1,984
phased haplotypes from the 1000 Genomes Project.39
Cell Lines
Lymphoblasts were isolated fromwhole blood collected in acid cit-
rate dextrose (ACD) tubes and transformed with Epstein-Barr virus
to make lymphoblastoid cell lines (LCLs) by the Baylor College of
Medicine Intellectual and Developmental Disabilities Research
Center Tissue Culture Core. LCLs were cultured in GIBCO RPMI
1640 media with 20% FBS, then 10% FBS, and 1% antimycotic/
antibiotic (all from Life Technologies) in 5% CO2.
RNA Extraction and cDNA Synthesis
Total RNAwas extracted from confluent, transformed lymphoblas-
toid cells using TRIzol (Invitrogen). RNA was cleaned using the
RNeasy kit (QIAGEN) and quantitated with a NanoDrop ND-
1000 spectrophotometer (NanoDrop). Complementary DNA
(cDNA) was synthesized using qScript cDNA SuperMix (Quanta
Biosciences) according to the manufacturer’s instructions
(input ¼ 1 mg RNA). cDNA quality was assessed via gel electropho-
resis (not shown). A mock cDNA synthesis reaction performed
without the reverse transcriptase mixture served as a negative
(‘‘No RT’’) control during cDNA PCR.
PCR and Sequencing of cDNA
cDNA (2 ml) was used as PCR substrate in a 25 ml reaction mix con-
taining 0.5 mM of each primer (Table S2) and 13 Promega PCR
Master Mix (Promega). Thermocycler conditions were as follows:
95C 3 2 min; 40 cycles of 95C 3 30 s, 57C 3 30 s, 72C 3
3 min; 72C 3 5 min. PCR products were sequenced by Sanger
di-deoxynucleotide sequencing (Lone Star labs; Baylor College of
Medicine Sequencing Core, Houston, TX, USA) using the above
cDNA PCR primers.
Quantitative RT-PCR
Quantitative RT-PCR (qPCR) assessing the expression level of
SLC30A6 was performed using the TaqMan assay (Life Technolo-
gies). The Hs01071782_m1 probe set was used for SLC30A6 (spans
the boundary of exon 9 and exon 10). The Hs02758991_g1 probe
set was used for GAPDH (control gene [MIM 138400]; probe set
spans the boundary of exon 6 and exon 7). The PCR amplification
step was performed with 1 ml cDNA utilizing TaqMan Fast
Advanced Master Mix (Life Technologies) and the 7900HT Fast
Real-Time PCR System (Applied Biosystems). Three technical rep-
licates were performed for each sample (subject or control).
The comparative Ct method was used to generate the relative
quantification (DCt) of the expression level of SLC30A6 over
GAPDH in an individual. The distribution of the DCt for
SLC30A6 was established by the control samples. The SLC30A6
DCt for the subject was compared to this distribution using the
empirical cumulative distribution function.Results
SPASTCNVs Exhibit Diverse Sizes, Genomic Positions,
and Exons Rearranged
We analyzed 51 heterozygous CNVs in SPAST (48 deletions
and 3 duplications), predominately identified in individ-The Ameruals with a diagnosis of spastic paraplegia (Table 1).
CNVs were most commonly discovered by multiplex liga-
tion-dependent probe amplification (MLPA; data not
shown). MLPA indicates only the exon(s) deleted or dupli-
cated by a CNV, not its boundaries (breakpoints), so we
fine-mapped each rearrangement using array comparative
genomic hybridization (aCGH). Array CGH confirmed
each CNV (Figures 1 and S1) and determined the approxi-
mate size, extent, and genomic content of each rearranged
interval, enabling junction-spanning (breakpoint) PCR
and sequencing reactions to be performed. PCR ampli-
fied 50 of 51 (98%) CNV breakpoints (Figure S2), and
sequencing delineated the breakpoint sequence and exact
coordinates of 49 (98%) of these rearrangements (Figure S3;
46 deletions and 3 duplications).
A diversity of CNV alleles were identified (Tables 1 and
S1, Figure 2A). To date, 40 different combinations of SPAST
exons have been reported to be deleted in individuals with
spastic paraplegia, and 2 duplicated;5,9,14,40,41 we now
contribute 12 novel rearrangements of SPAST exons
(Table 1), including 2 novel duplications.
Of the CNVs we report, 36 (71%) occur in a single sub-
ject, and five groups of individuals had identical (shared
regions of breakpoint microhomology) SPAST CNVs:
Ruhr 9 and Ruhr 10 (del exon 1); Ruhr 3 and Ruhr 5 (del
exons 2–9); Ruhr 13 and Ruhr 18 (del exons 8–17 and
exon 1 of SLC30A6); A4, A8, A9, and SPAST_1 (partial
del exon 17); and A1 and BAB 3327 (del exon 17; also iden-
tical to A39 from Boone et al.14). Identical CNVs in multi-
ple subjects suggests either recurrent CNV formation or
that individuals within a group are related or are the
same individual. To investigate these possibilities, we
analyzed 15 short tandem repeat alleles (STRs) and gender
in these individuals (Table S3). No subjects sharing an iden-
tical CNV were monozygotic twins or the same individual,
and in only one case (A1 and BAB 3327) were two such in-
dividuals consistent with a parent-child pair. To identify
whether identical CNVs are observed on the same haplo-
type (i.e., potentially identical by descent) or on different
haplotypes (i.e., identical by state, suggesting recurrent
events), common SNPs flanking the CNVs were genotyped
to establish a local haplotype. No flanking SNPs differ
among individuals sharing the same CNV, thus failing to
provide specific evidence for recurrence (Figure S6). For
CNVs shared between Ruhr 13 and Ruhr 18, the haplotype
surrounding the CNV is uncommon (5.1%), making recur-
rent events particularly unlikely. In other groups, the CNVs
occurred on the most common haplotype.
We combined data from the 49 CNV breakpoint junc-
tions delineated above with data from five SPAST CNVs
we reported previously14,26,27 and three additional pub-
lished SPAST CNVs,11,28,40 totaling 57 rearrangements
and representing every SPAST CNV>30 bp for which exact
breakpoint coordinates have been identified (Tables 1 and
S1; Figure 2A). These CNVs range from 1,340 bp to
1,283,930 bp in size, with a mean of 73.1 kb, a median
of 16.5 kb, and a distribution skewed toward smallerican Journal of Human Genetics 95, 143–161, August 7, 2014 145
Table 1. Subjects and SPAST CNVs
Subject
Del
versus
Dup
SPAST Exon(s)
Affected
(of 17)
Other Genes Deleted
or Duplicated
CNV
Size (kb)
Spastic
Paraplegia Origin
Novel
Rearrangementa Notes
A1 del 17 – 5.5 y USA –
A2 del 17 – 14.4 y USA – complex
A3 del 17 SLC30A6 ex 1–5 (of 15) 24.6 y USA –
A4 del 17 (partial) – 2.7 y USA y
A5 del 17 SLC30A6 ex 1–2 (of 15) 18.4 y USA –
A6 del 17 SLC30A6 ex 1–2 (of 15) 25.7 y USA –
A8 del 17 (partial) – 2.7 y USA y
A9 del 17 (partial) – 2.7 y USA y
A10 dup 13–15 – 6.2 y USA y tandem, directly
oriented duplication
BAB 3166 del 13 – 1.3 n (at age 16) USA NA reported in Boone
et al.26
BAB 5112 del 5–17 SLC30A6, NLRC4, YIPF4,
BIRC6, MIR558, MIR4765,
and TTC27 ex 1–5 (of 20)
559.3 y USA y
BAB 3200 del 1–7 DPY30 ex 1–3 (of 5) 87.2 y USA NA complex; reported
in de Ligt et al.27
BAB 3327 del 17 – 5.5 y USA –
SPAST_1 del 17 (partial) – 2.7 ?b USA y
SPAST_3 dup 2–17 SLC30A6, NLRC4, YIPF4,
and BIRC6 ex 1–46 (of 74)
432.2 ?b USA y tandem, directly
oriented duplication
Spain 1 del 5–16 – 43.4 y Spain y
Spain 2 del 13–17 SLC30A6, NLRC4, YIPF4,
MIR558, and BIRC6 ex
1–66 (of 74)
455.0 y Spain y
Spain 3 del 3–17 SLC30A6 ex 1–5 (of 15) 95.7 y Spain –
Spain 4 del 8–17 SLC30A6 ex 1–5 (of 15) 60.7 y Spain –
Spain 5 del 1 – 12.6 y Spain –
Spain 6 del 2–17 SLC30A6 and NLRC4 ex
5–9 (of 9)
170.1 y Spain –
Spain 7 del 10–16 – 16.0 y Spain –
Spain 8 del 2–7 – 48.9 y Spain y
Spain 9 del 6–7 – 5.0 y Spain –
JKF B del 16 – 2.0 y USA –
JKF C dup 9 – 6.7 y USA y tandem, directly
oriented duplication
Ruhr 3 del 2–9 – 65.4 y Germany –
Ruhr 4 del 1 – 20.5 y Germany –
Ruhr 5 del 2–9 – 65.4 y Germany –
Ruhr 6 del 5–6 – 8.3 y Germany –
Ruhr 7 del 17 (partial) – 5.1 y Germany y
Ruhr 9 del 1 – 4.0 y Germany –
Ruhr 10 del 1 – 4.0 y Germany –
Ruhr 11 del 2–7 – 33.5 y Germany y
(Continued on next page)
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Table 1. Continued
Subject
Del
versus
Dup
SPAST Exon(s)
Affected
(of 17)
Other Genes Deleted
or Duplicated
CNV
Size (kb)
Spastic
Paraplegia Origin
Novel
Rearrangementa Notes
Ruhr 12 del 1 – 16.3 y Germany –
Ruhr 13 del 8–17 SLC30A6 ex 1 (of 15) 44.8 y Germany –
Ruhr 14 del 16–17 SLC30A6 ex 1–4 (of 15) 31.7 y Germany –
Ruhr 15 del 2–12 – 72.9 y Germany y
Ruhr 16 del 5 – 1.9 y Germany –
Ruhr 17 del 9–17 (partial) – 27.5 y Germany y
Ruhr 18 del 8–17 SLC30A6 ex 1 (of 15) 44.8 y Germany –
Ruhr 21 del 10–17 (partial) – 20.9 y Germany y
Ruhr 23 del 17 – 17.6 y Germany –
Ruhr 26 del 13–16 – 7.3c y Germany –
Ruhr 27 del 17 SLC30A6 ex 1–2 (of 15) 24.1 y Germany – complex
Ruhr 28 del 1 (partial) – 16.5 y Germany –
Ruhr 29 del 8–17 SLC30A6, NLRC4, YIPF4,
BIRC6, MIR558, MIR4765,
TTC27, LINC00486,
LOC100271832, LTBP1,
5S_rRNA
1,283.9 y Germany –
Ruhr 31 del 8–9 – 9.3 y Germany –
Ruhr 32 del 2–13 – 59.4c y Germany y
Park 1 del 5–7 – 11.7 y Korea –
Park 2 del 5 (partial)–7 – 8.1 y Korea y
Park 3 del 8–9 – 8.9 y Korea –
Park 4 del 4–17 SLC30A6 ex 1–9 (of 15) 100.5 y Korea –
A37 del 17 – 10.8 y USA NA reported in Boone
et al.14
A38 del 17 – 16.8 y USA NA complex; reported
in Boone et al.14
A39 del 17 – 5.5 y USA NA reported in Boone
et al.14
Iwanaga del 1 (partial) – 2.3 y Japan NA reported in Iwanaga
et al.28
Mitne-Neto dup 10–12 – 4.0 y Brazil NA reported in Mitne-
Neto et al.11; tandem,
directly oriented
duplication
Miura del 1–4 DPY30 ex 1–3 (of 5) 69.8 y Japan NA reported in Miura
et al.40
Abbreviations are as follows: ex, exon; y, yes; n, no; NA, not applicable; –, no or none.
aBased on SPAST exon or combination of exons rearranged and ploidy (del versus dup). Rearrangement of part of an exon is considered to be distinct from
rearrangement of the whole exon. Previously published CNVs derived from Loureiro et al.,5 A´lvarez et al.,9 Boone et al.14,26 Sulek et al.,41 and Myers et al.42
bPhenotype unknown.
cCNV breakpoint could not be sequenced. CNV length is an average of the minimum and maximum CNV interval identified by aCGH.rearrangements (Figure 3). Thus, the majority of SPAST
CNVs are of modest size when compared with the gene
itself (94 kb).
All known SPAST duplications (Table 1, Figure 2) are tan-
dem and directly oriented.We previously noted that SPAST
duplications are significantly underrepresented whenThe Amercompared with deletions among subjects with SPG4,14 a
trend that continues in the data presented here (Table 1).
The pathogenic duplications in subjects A10 (exons 13–
15) and Mitne-Neto (exons 10–12) are both expected
to shift the reading frame; interestingly, the pathogenic
duplication in JKF C (exon 9) is predicted to be in-frame.ican Journal of Human Genetics 95, 143–161, August 7, 2014 147
Figure 1. Targeted aCGH Confirms and Maps CNVs in SPAST
Array CGH log2 plots are aligned with models of SPAST and nearby genes. Very small CNVs are indicated by arrows. Coordinates refer to
chromosome 2. No SPAST CNV was identified in either blood- or cell-culture-derived DNA from the control individual, BAB 3099.
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Figure 2. CNVs in SPAST Rearrange Diverse Exons and Have Breakpoints Predominately Localizing to Pairs of Alus in Direct
Orientation
(A) CNVs are plotted by exact coordinates obtained by sequencing (black bars) and include both duplications (denoted ‘‘Dup’’) and
deletions (all others). Repetitive elements at CNV breakpoints are indicated by colored shapes and aligned with the RepeatMasker track
(bottom, via UCSC Genome Browser) by colored lines. The genomic orientation of Alus is denoted by a right-facing (þ) or left-facing ()
pentagon. Of 59 breakpoints, 39 (66%) localize to directly oriented Alu pairs. Note that BAB 3166 was identified in a young individual
with no current spastic paraplegia26 and that the phenotypes of SPAST_1 and SPAST_3 are unknown; thus, these three CNVs might or
might not be pathogenic. *Complex CNV (these CNVs are plotted as simple CNVs with only the first and final breakpoint repeat indi-
cated). The breakpoints of Ruhr 26 and Ruhr 32 were not found, so these CNVs are not included.
(B) A moving average of Alu density (calculated in overlapping blocks of ten Alu elements) is aligned with (A), demonstrating that SPAST
is overall an Alu-rich gene with ‘‘neighborhoods’’ of even higher Alu density. Alu data were downloaded from RepeatMasker.
(C) Zoomed-out plot of Alu density over a ~1.1 Mb section of chromosome 2.CNV Breakpoints Predominately Localize to Pairs of
Alu Elements in Direct Orientation
CNV boundaries, or breakpoints, occasionally preferen-
tially localize to repetitive genomic elements, which canThe Amerplay a role in mediating CNV formation.13,18 Repetitive
elements present at the breakpoints of SPAST CNVs are
shown in Figure 2 and listed in Table 2. Of 57 sequenced
SPAST CNV breakpoints, 39 (68%) localize to directlyican Journal of Human Genetics 95, 143–161, August 7, 2014 149
Figure 3. CNV Size: Skew toward Small Rearrangements and Association with Breakpoint Repeat Architecture
SPAST CNVs, plotted in ascending size order. Most SPAST CNVs are small (median size ¼ 16.5 kb). CNVs flanked by Alu pairs (gray) are
significantly smaller than remaining CNVs (green) (Kruskal-Wallis rank sum test, p ¼ 0.00856; identical CNVs in multiple individuals
[e.g., Ruhr 3 and 5] are collapsed to single entries, and CNVs published by other authors [which may be biased toward small, non-Alu-
Alu-mediated events] are removed). *Complex CNV. BAB 5112 is LINE-LINE mediated. CNVs <25 kb are magnified in the inset to show
detail. The size of complex CNVs is rounded to the nearest 0.1 kb.oriented pairs of Alu repeats. Such CNVs demonstrate
breakpoint ‘‘signatures’’ consistent with Alu-mediated
CNV formation (i.e., the rearranged genome contains a
complete hybrid Alu, each ‘‘half’’ of which is derived
from one of the two breakpoint Alus that flanked the
deleted or duplicated region prior to its loss or gain, respec-
tively;22 Figure S3).
Breakpoint Alu pairs exhibit variable sequence identity
(range ¼ 75.8%–90.7%), possess differing numbers of
bases of microhomology at the hybrid junction (range ¼
5–38 bp), and comprise distinct Alu families (Table 2).
Of the 39 breakpoint Alu pairings, 33 (85%) consist of
Alus from different families. Several Alus are present at
the breakpoints of multiple CNVs. These data are consis-
tent with analyses of multiple Alu-mediated CNVs at
additional disease loci (Table 4). The repeat present at a
breakpoint of the greatest number of different CNVs is
an AluY (Spain 7, A38, Ruhr 23, Ruhr 27, A6), as observed
previously.16 Breakpoint crossover/microhomology loca-
tions occupy various positions within the Alu substrate
pairs (Figure S4).
The eight largest CNVs are not Alu mediated (Figure 3).
To determine statistically whether CNV size correlates
with the presence or absence of Alus at CNV breakpoints,
we collapsed CNVs found in multiple individuals (e.g.,
Ruhr 3 and 5) into single entries and removed the three
SPAST CNVs described by other authors, which may be
biased toward small, non-Alu-mediated events because
such CNVs are more readily mapped and sequenced.150 The American Journal of Human Genetics 95, 143–161, August 7Among this data set, CNVs flanked by Alu pairs are signif-
icantly smaller than non-Alu-mediated CNVs (Figure 3;
Kruskal-Wallis rank sum test, p ¼ 0.00856).
Three CNVs with proximal and distal breakpoints in
Alus are potentially complex (A38, A2, and Ruhr 27). A38
has been described14 and is consistent with formation by
two or three template switches during DNA replication or
by NAHR and a novel, familial Alu polymorphism. The
origin of A2 is consistent with two template switches or a
small (11 bp) insertion. The origin of Ruhr 27 is consistent
with two template switches, two distinct NAHR events, or
an NAHR event and a novel, familial Alu polymorphism. It
is unknown whether any of these CNVs is de novo, and
parental DNA is unavailable.
In addition to the 39 CNVs in our cohort with pairs of
Alus at breakpoints, other signatures are present in 32%
of junctional sequences. These include 13 instances of
microhomology not localizing to repeat pairs, two appar-
ently blunt end ‘‘clean breaks,’’ one LINE-LINE recombina-
tion (BAB 5112), one 1 bp insertion, and one potentially
complex CNV (BAB 3200) (Figure S3).
Some Breakpoint Alus Contain a 13-nt Consensus
Motif Enriched at Meiotic Recombination Hotspots
A 13-nucleotide motif (consensus ¼ CCNCCNTNNCCNC)
has been delineated and found in proximity to and in asso-
ciation with >40% of meiotic recombination crossover
hotspots, at NAHR crossover hotspots in low-copy repeats
flanking some genomic disorder regions, and is bound, 2014
Table 2. Repeats Present at CNV Breakpointsa
Subject
Left
Breakpoint
Repeat
Right
Breakpoint
Repeat
Microhomology
(bp)
% Identity
of Repeatsb
A1 AluSxc AluY 26 81.7
A2c AluSx AluSx1 complex complex
A3 AluSx1c AluY 7 86.9
A4 AluSx1c AluSp 15 84.8
A5 AluSx1c AluSp 9 88.6
A6 AluY AluSx3c 21 84.6
A8 AluSx1c AluSp 15 84.8
A9 AluSx1c AluSp 15 84.8
A10 AluSz6 AluSg 31 80.1
BAB 3166 – – 6 –
BAB 5112 L1PA5 L1PA7 21 90.6
BAB 3200 AluSc – complex –
BAB 3327 AluSxc AluY 26 81.7
SPAST_1 AluSx1c AluSp 15 84.8
SPAST_3 – – 4 –
Spain 1 L1PA5 AluJb 4 –
Spain 2 – AluSp 2 –
Spain 3 AluSz6 – 2 –
Spain 4 AluSq L1M4 8 –
Spain 5 AluSz AluSz 26 80.6
Spain 6 AluSg4 – 1 –
Spain 7 AluSc AluY 15 84.6
Spain 8 AluSg4 AluYc 9 83.7
Spain 9 – – 6 –
JKF B AluSg AluY 14 82.1
JKF C AluSz AluSxc 35 82.8
Ruhr 3 AluJo AluJb 19 77.6
Ruhr 4 AluSz AluY 25 75.8
Ruhr 5 AluJo AluJb 19 77.6
Ruhr 6 Tigger4a AT_rich 1 bp ins –
Ruhr 7 AluSp AluSp 8 87.9
Ruhr 9 AluSx3 AluSzc 5 82.7
Ruhr 10 AluSx3 AluSzc 5 82.7
Ruhr 11 AluSx1 AluSz 38 82.7
Ruhr 12 AluSx AluSx3 9 77.4
Ruhr 13 AluSz6 AluSp 24 84.4
Ruhr 14 AluJb AluSzc 18 77.6
Ruhr 15 AluJo AluY 22 79.9
Ruhr 16 AluSx AluSp 20 79.1
Ruhr 17 – – 3 –
Table 2. Continued
Subject
Left
Breakpoint
Repeat
Right
Breakpoint
Repeat
Microhomology
(bp)
% Identity
of Repeatsb
Ruhr 18 AluSz6 AluSp 24 84.4
Ruhr 21 AluY AluSp 33 83.2
Ruhr 23 AluY AluSz 11 85.6
Ruhr 26d NA NA NA NA
Ruhr 27 AluY AluSp complex complex
Ruhr 28 – L1M4 4 –
Ruhr 29 L1MC2 L1M5 0 –
Ruhr 31 AluYc AluY 5 90.7
Ruhr 32d NA NA NA NA
Park 1 AluSx1 AluSp 7 80.7
Park 2 – FLAM_C 3 –
Park 3 AluYc AluSxc 8 81.1
Park 4 – AluSq 4 –
A37 AluY AluY 8 89.4
A38 AluY AluSx3 complex complex
A39 AluSxc AluY 26 81.7
Iwanaga – AluSx3 1 –
Mitne-Neto – L1M7 0 –
Miura AluSx1 AluJb 9 77.1
Left, telomeric; right, centromeric; –, not applicable or no repeat present.
aAll Alu-Alu and LINE-LINE pairs are in matching genomic orientation (both
negative or both positive) (Table S1, Figure 2A), with the exception of Ruhr 29.
bNumber of identical bases divided by smaller repeat length. Comparison by
Needleman-Wunsch Global Alignment algorithm.
cRepeat contains the consensus 13-nt sequence associated with meiotic recom-
bination hotspots, some NAHR breakpoint regions, and bound in vitro by
PRDM9.42–44 The Alu from which the inserted sequence in the complex A2 re-
arrangement derives contains this sequence.
dBreakpoint unable to be sequenced (Ruhr 26) or failed breakpoint PCR
(Ruhr 32).
The Amerin vitro by PRDM9, a protein with a role in meiotic homol-
ogous recombination.42–44 Alus are enriched for this motif.
We analyzed sequence within or flanking SPAST (chr2:
32,280,000–32,412,000) and found 24 of these motifs, 23
of which are in or overlap Alus (Figure 4B, Table 3). This
motif is present in one breakpoint Alu of ten Alu-mediated
CNVs, at both breakpoint Alus of one CNV (Park 3), and in
the Alu from which inserted breakpoint sequence is
derived in one apparently complex rearrangement (A2)
(Figure 4).
Twenty-eight CNVs are Alu mediated, unique, and
noncomplex. Of these CNVs’ 56 breakpoint Alus, 12
(21%) contain the 13-mer consensus motif. To investigate
whether this represents an enrichment of the 13-mermotif
in breakpoint Alus of Alu-mediated CNVs (and thus may
be involved in their formation), we made the following
comparisons to other groups of Alus. First, seven non-
Alu-mediated CNVs have a single breakpoint in an Aluican Journal of Human Genetics 95, 143–161, August 7, 2014 151
Figure 4. The Consensus 13-mer, CCNCCNTNNCCNC, Associated with Meiotic Recombination/NAHR Hotspots Is Present at Break-
point Alus of Some Alu-Mediated CNVs
(A) CNVs (black bars) displayed with breakpoint Alus (pentagons; filled and intersected by a colored line if they contain the consensus
13-mer [CCNCCNTNNCCNC] associated with meiotic recombination/ NAHR hotspots42,43). This motif is present at a single breakpoint
Alu of ten Alu-mediated CNVs, at both breakpoint Alus of one CNV (Park 3), and in the Alu from which inserted breakpoint sequence is
derived in one apparently complex rearrangement (A2). Abbreviation: Dup, duplication.
(B) All instances of the 13-mer (black arrowheads).
(C) SINE elements (RepeatMasker track via UCSC Genome Browser).(Figure 2, Table 2); of these, none contain the 13-mer (0%);
this paucity was not significant (p ¼ 0.329, two-tailed
Fisher exact test). Second, there are 188 Alus within
and flanking SPAST (chr2: 32,280,000–32,412,000; Fig-
ure 4C); 23 of these contain the 13-mer (12%); this
decrease is not significant (p ¼ 0.126, two-tailed Fisher
exact test).
Deletions Resulting in Chimeric Genes
Although 28 CNVs are purely intragenic, seven CNVs
extend 50 of SPAST, and for 22 CNVs a breakpoint maps
beyond the 30 end of the gene; of these CNVs overlapping
SPAST, 17 affect additional genes (Figure 2A, Table 1). Two
deletions extending beyond the 50 end of SPAST (BAB 3200
and Miura) have telomeric breakpoints in another gene,
DPY30 (MIM 612032). DPY30 is in reverse genomic orien-
tation with SPAST; thus, a chimeric SPAST-DPY30 gene is
less likely to result from these deletions. The effect of het-
erozygous loss of function of DPY30 is unclear, as an asso-
ciation between DPY30 and any human disease has not
been described, although its ortholog appears to be devel-
opmentally important in C. elegans (reviewed by Miura
et al.40).
Thirteen deletions (and one duplication) that extend
beyond the 30 end of SPAST have centromeric breakpoints
in other genes (SLC30A6 ¼ 10 deletions; NLRC4 [MIM
606831] and TTC27 ¼ 1 deletion each; BIRC6 [MIM
605638] ¼ 1 deletion and 1 duplication) (Figure 5).
SLC30A6, BIRC6, and TTC27 are in direct orientation
with SPAST; thus, the 12 deletions of the 30 end of SPAST152 The American Journal of Human Genetics 95, 143–161, August 7and the 50 end of these genes form chimeric genes in these
subjects’ genomes (Figure 5A). Multiple transcript isoforms
have been identified for SLC30A6, BIRC6, and TTC27;
thus, multiple fusion transcripts incorporating 50 SPAST
exons and 30 exons of these genes are possible in subjects
with such deletions (Figure 5B). Eight of twelve deletions
have at least one predicted in-frame transcript. The
SPAST_3 duplication is not anticipated to disrupt SPAST
and thus is not likely to convey pathogenic changes to
the spastin protein (consistent with this subject’s un-
known status for spastic paraplegia). However, it creates
an additional BIRC6:SPAST chimeric gene, the predicted
fusion transcript of which is in-frame (Figure 5C). RNA
was not available from any of these deletion or duplication
subjects to examine experimentally for fusion transcripts.
None of the genes potentially involved in a fusion tran-
script (SLC30A6, BIRC6, and TTC27), nor any of the other
genes affected by deletions spanning beyond the 30 end
of SPAST (NLRC4, YIPF4, MIR558, MIR4765, LINC00486,
LOC100271832, LTBP1 [MIM 150390], and 5S_rRNA), is
associated with Mendelian disease. Thus, the potential
consequences to gene regulation or function of CNVs
affecting these loci are unknown.
Deletion of SPAST Exon 17 Can Generate Fusion
Transcripts with SLC30A6
Because SLC30A6 is the nearest gene downstream of SPAST,
SPAST deletions with 30 breakpoints in the 8 kb region be-
tween the two genes could potentially affect one or more
SLC30A6 regulatory regions and/or result in splicing, 2014
Table 3. 13-mer CCNCCNTNNCCNC Associated with Meiotic
Recombination/NAHR Hotspots within and Flanking SPASTa
Coordinate Orientation Within Alu?
Alu Used in CNV
Breakpoint?
chr2: 32,290,968 negative – –
chr2: 32,292,376 positive AluSz Ruhr 9, Ruhr 10
chr2: 32,294,873 positive AluY –
chr2: 32,300,868 positive AluSz –
chr2: 32,303,490 positive AluSz6 A2 (complex)
chr2: 32,311,592 negative AluSx –
chr2: 32,317,837 negative AluSx –
chr2: 32,323,295 negative AluJr –
chr2: 32,337,660 positive AluSg –
chr2: 32,339,234 negative AluJo –
chr2: 32,346,229 negative AluSx1
(overlaps)
–
chr2: 32,351,109 positive AluY Park 3, Ruhr 31,
Spain 8
chr2: 32,355,085 negative AluJr
(overlaps)
–
chr2: 32,360,010 positive AluSx Park 3, JKF C
chr2: 32,371,388 negative AluJo –
chr2: 32,375,404 positive AluSc –
chr2: 32,378,630 positive AluSx1 A3, A4, A5, A8, A9,
SPAST_1
chr2: 32,378,906 negative AluSx A1, A39, BAB 3327
chr2: 32,394,608 negative AluY –
chr2: 32,398,678 positive AluSx3 A6
chr2: 32,399,507 positive AluJo –
chr2: 32,402,087 positive AluSz Ruhr 14
chr2: 32,406,792 negative AluSx –
chr2: 32,411,515 negative AluSx1 –
aChr2: 32,280,000–32,412,000.between the last remaining SPAST exon and SLC30A6.
Seven such SPAST deletions exist among our data set, their
30 breakpoints mapping within 6.5 kb to<1 kb of SLC30A6
(Figure 5). An additional seven deletions have 30 break-
points within the final exon (exon 17) of SPAST (Figure 5).
Nervous system RNA was not available from these sub-
jects; however, a lymphoblastoid cell line from one subject
with a complete exon 17 deletion (BAB 3327) was ob-
tained. cDNA was prepared from this cell line and from a
healthy control individual, BAB 3099;45 both blood-
derived and lymphoblastoid-cell-line-derived DNA from
the control individual is free of SPAST CNVs as determined
by aCGH (Figure 1). Two PCRs of cDNA were performed,
one with primers closely flanking the deletion (forward
primer in exon 16 of SPAST and reverse primer in
SLC30A6 exon 2) and one with primers flanking a largerThe Amerarea (forward primer in SPAST exon 12 and reverse primer
in SLC30A6 exon 7, the first constitutive exon of this gene)
(Figure 6). A few faint fusion transcript bands were present
in the control individual. However, abundant, robust
fusion transcript bands were present in the SPAST deletion
CNV subject (BAB 3327) (Figures 6A–6C). Sequencing of all
PCR products confirmed splicing from SPAST to SLC30A6
(Figure 6E), further indicating that deletion of SPAST
exon 17 can alter the expression/transcript structure of a
downstream gene.Effect of a SPAST Exon 17 Deletion on SLC30A6
Expression Level
The possibility exists that, by creating SPAST:SLC30A6
fusion transcripts or disrupting SLC30A6 upstream regula-
tory sequences, the SPAST exon 17 deletion in BAB
3327 may affect SLC30A6 expression level.46 qPCR
indicated that the level of expression of SLC30A6 in a
BAB3327 lymphoblastoid cell line does deviate signifi-
cantly from that of eight pooled control lymphoblastoid
cell lines (50th centile versus controls, empirical cumula-
tive distribution function) (Figure 6).Discussion
SPAST CNVs: Diverse Sizes, Boundaries, and Exons
Rearranged
We delineated breakpoint junctions for 49 SPAST CNVs
and document extensive diversity of disease-associated re-
arrangements in this gene, even for CNVs affecting a given
exon. By increasing the number of published, disease-
causing SPAST CNVs with known breakpoints from 7 to
54, we provide a resource for evaluating the pathogenicity
of CNVs in SPAST identified during the course of genomic
testing. Predicted in-frame deletions of exons 4, 8, and 9 in
individuals with SPG4 suggest that these exons are indis-
pensable, and a pathogenic, predicted in-frame duplica-
tion of exon 9 (24 amino acids) reinforces the sensitivity
of the spastin AAA (ATPase Associated with various cellular
Activities) domain to mutation47 (Figure S5). No SPAST
exons have been demonstrated to be dispensable. How-
ever, exon 2 or 3 deletions have not been reported in per-
sons with SPG4; thus, these in-frame exons may be
candidates for exon skipping48 for individuals with patho-
genic point mutations in them.
The CNV allele size versus frequency spectrum is skewed
toward rearrangements of modest size relative to SPAST. A
skewing toward small CNVs is reminiscent of the overall
distribution of CNVs in personal genomes.49 It may also
reflect the mechanism(s) of formation of SPAST CNVs, dis-
cussed below.Alu Elements Destabilize SPAST, Leading to CNVs
with Unique Properties
We found that more than two-thirds of SPAST CNVs
have breakpoints in pairs of directly oriented Alus. Thus,ican Journal of Human Genetics 95, 143–161, August 7, 2014 153
Figure 5. SPAST CNVs Extending into 30 Genes Create Chimeric Genes, and Deletions Involving the Final Exon of SPASTMight Create
SPAST:SLC30A6 Fusion Transcripts or Alter SLC30A6 Expression
(A–C) Deletions extending into 30 genes.
(A) Fourteen CNVs (black bars) extend into genes 30 of SPAST (13 deletions, 1 duplication). Three of the downstream genes
(SLC30A6, BIRC6, TTC27) are in direct orientation with SPAST; thus, SPAST deletions intersecting these 30 genes potentially yield
chimeric genes.
(B) Potential fusion transcripts resulting from the deletions shown in (A) for which the 30 intersected gene is directly orientedwith SPAST.
Potential fusion transcripts are based only on known splice isoforms of the 30 genes and include all SPAST exons present, although other
(legend continued on next page)
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Alu-mediated CNV formation is the predominant, but
not exclusive, mechanism generating rearrangements in
SPAST. The observed predominance of Alu-mediated
CNVs suggests that the Alu-rich genomic architecture of
SPAST (36% of the gene with segments of even higher
Alu density;14 Figure 2B) renders this locus susceptible to
a variety of genome rearrangements and may explain
why an appreciable percentage of mutations causing
SPG4 are CNVs.
Alu-mediated CNVs in our cohort share properties with
Alu-mediated CNVs at other disease loci, including the
presence of breakpoint microhomology, rearrangement
between different Alu family members, and small size
(Table 4). We found that Alu-mediated CNVs in SPAST are
smaller than non-Alu-mediated CNVs (which include the
eight largest rearrangements in our cohort). This could
reflect a ‘‘boundary’’ created by a zone of low Alu den-
sity near SPAST. Alternatively, it suggests a potential size
preference or limit as a general feature of Alu-mediated
CNV formation. Human-specific Alu-mediated CNVs22
are even smaller (median 468 bp, mean 806 bp; range
101–7,255 bp) than Alu-mediated CNVs in disease loci,
potentially a contributing factor to their becoming fixed
in a species.
Proposed Mechanisms Generating
Alu-Mediated CNVs
The hypothesized mechanism for Alu-Alu-mediated CNV
formation has been homologous recombination between
nonallelic Alus, i.e., Alu-Alu recombination.20,50 The SPAST
CNVs we report are generally consistent with this model:
pairs of Alus are directly oriented and render a complete,
hybrid Alu in the recombined genome; complex rear-
rangements are infrequent.43 However, the short length
(<300 bp) and low percent identity (<91%) shared by
Alus within each pair may be insufficient to meet the pre-
sumed requirements of ectopic homologous recombina-
tion derived from observational studies of NAHR at
LCRs.51,52 Furthermore, the three complex Alu-mediated
CNVs are inconsistent with formation by NAHR unless a
familial Alu polymorphism existed prior to the rearrange-
ment. Some of the Alus at breakpoints of Alu-mediated
CNVs contained the 13-nucleotide consensus motif en-
riched at meiotic recombination hotspots and at some
LCRs involved in NAHR.42,43 Although intriguing, any
enrichment of this consensus motif in breakpoint Alus ofsplice variants are possible. Predicted in-frame splicing is shown in bl
is not shown, because this gene is oriented oppositely to SPAST.
(C) Potential fusion transcript resulting from the duplication in subj
duplication of three genes (SLC30A6,NLRC4, YIPF4) and a potential i
SPAST; the normal, diploid copy number of full-length SPAST and BI
(D and E) Deletions involving the final exon of SPAST.
(D) Deletions with 30 breakpoints in the intergenic space between SPA
SPAST (exon 17) (bottom, ‘‘interrupt exon 17’’). The former group of
SLC30A6 regulatory sequence (potential regulatory sequences show
result in fusion transcripts with SLC30A6 by eliminating splicing to
(E) Potential fusion transcripts resulting from the deletions shown in
isoforms of SLC30A6 and include all SPAST exons present. Black, pre
The AmerAlu-mediated CNVs was not significant when compared
to either Alus present at one breakpoint of non-Alu-medi-
ated CNVs or to all Alus within and near SPAST. Finally,
an analysis of previous studies at other loci (Table 4)
demonstrates that moderate identity breakpoint Alu pairs
and occasional complex events are general features of
Alu-mediated CNVs. These findingsmay implicate an alter-
native non-homologous-recombination mechanism for
Alu-mediated CNV formation.14
One alternative rearrangement mechanism may be
microhomology-mediated DNA repair,53 for example
microhomology-mediated end joining (MMEJ) or fork
stalling and template switching (FoSTeS)/microhomol-
ogy-mediated break-induced replication (MMBIR). These
mechanisms are consistent with the microhomology pre-
sent at the breakpoints of Alu-mediated CNVs among our
and others’ data (Table 4). MMEJ may explain the predom-
inance of deletions over duplications. FoSTeS/MMBIR may
explain the occasional apparently complex Alu-mediated
CNV.14
Another alternative mechanism may be single-strand
annealing (SSA).54,55 This double-strand break (DSB) repair
pathway involves the annealing of directly oriented re-
peats flanking the DSB after they are made single-stranded
by 50 to 30 end resection. The removal of the 30 flaps and
filling of gaps by DNA synthesis then results in a simple,
small deletion. In a study of translocation mechanisms,
Elliott et al.56 induced double-stranded breaks adjacent to
a human Alu element on each of two nonhomologous
chromosomes in cultured mouse cells; when the Alu
elements were identical, SSA was the predominant mecha-
nism generating translocations between these chromo-
somes. However, when the Alus were only 80% identical,
the frequency of SSA diminished such that NHEJ became
the predominant translocation-generating mechanism.
Similarly, in yeast, a decrease of identity between two
205 bp repeats flanking a DSB site from 100% to 97%
decreased the rate of SSA by 6-fold.57
Another potential contributing mechanism could be
homeologous recombination, reduced-frequency recombi-
nation between substrates that are somewhat but not
perfectly identical.58–60 This model is consistent with the
low percent identity (75.8%–90.7%) shared by breakpoint
Alu pairs in our study.61 In addition, in 33 of 39 (85%) Alu-
Alu events in this study, the substrate pairs were from
different Alu families. Whereas NAHR generates recurrentack, out-of-frame in red. The deletion intersecting NLRC4 (Spain 6)
ect SPAST_3. This tandem, directly oriented duplication results in
n-frame transcript joining exons 1–46 of BIRC6with exons 2–17 of
RC6 are left intact.
ST and SLC30A6 (top, ‘‘span exon 17’’) or within the final exon of
deletions may alter SLC30A6 expression by eliminating upstream
n by H3K27Ac track from UCSC), and both groups of CNVs may
SPAST exon 17.
(D). Potential fusion transcripts are based only on known splice
dicted in-frame; red, predicted out of frame.
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Figure 6. A Deletion of SPAST Exon 17 Yields Multiple SPAST:SLC30A6 Fusion Transcripts
(A–D) PCR primers (arrows above and below gene models in D) were designed to detect SPAST:SLC30A6 fusion transcripts in cDNA from
subject BAB 3327, who has a deletion encompassing SPAST exon 17 (black bar in D). One primer set (F1 and R1) closely flanks the
deletion, and the other (F2 and R2) spans a greater distance to account for alternative splicing known to exist in SLC30A6 (exon 7 is
the first constitutive exon in this gene). PCR of cDNA (A) reveals multiple transcripts in BAB 3327 not present in the control individual
(BAB 3099). The majority of bands (white arrows) were extracted and sequenced. One extracted band (blue arrow) failed sequencing.
Four bands (gray arrows) required a second preparation/electrophoresis to be visualized, extracted, and sequenced (B and C, white
arrows).
(legend continued on next page)
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CNVs with high formation rates during meiosis,62 our data
and others’ (Table 4) demonstrate that Alu-mediated CNVs
are mostly or entirely nonrecurrent; thus, the formation
rate of any particular rearrangement is low, again consis-
tent with homeologous recombination.63 Although the
probability of any one Alu-mediated CNV occurring is
miniscule, with more than one million Alus in the
genome, the cumulative ability of Alus to act as a recombi-
nation substrate and generate genomic rearrangements
may be substantial.
SPAST deletions predominate over duplications. This
suggests that, if formed by recombination, these events
are most often intrachromatidal. Because Alus in close
linear proximity along the same chromatid are generally
expected to be in close three-dimensional proximity,64
and because three-dimensional proximity has been sug-
gested to be important for generation of rearrange-
ments,65 then perhaps small size is a general feature of
Alu-mediated CNVs that is facilitated by chromosomal
conformation itself. Long-range interactions, chromatin
compartments,64 tethering of Alus, and genome reorgani-
zation during the cell cycle66 could also shape the spatial
relationships of Alus and thus their probability of acting
as rearrangement substrates. If these CNVs are formed by
replicative template switching, small rearrangement size
would be consistent with the known tendency of this pro-
cess to occur more frequently over short distances.
Deletions Can Result in Chimeric Genes and Fusion
Transcripts
Almost half of the CNVs we report extend beyond the
boundaries of SPAST, many of which interrupt other genes.
Although none of these other genes is known to be associ-
ated with Mendelian disease, their disruption could have
phenotypic consequences. Moreover, 12 deletions extend-
ing 30 of SPAST form chimeric genes that may yield fusion
transcripts, also of unknown phenotypic consequence. Of
note are the deletions forming chimeric genes between
SPASTand SLC30A6 (solute carrier family 30, member 6) en-
coding a zinc transporter, ZnT6. Zinc and zinc transporter
(includingZnT6)dynamicshavebeendescribed tobealtered
in the brains of humans with Alzheimer disease and rodent
models of dementia.34,35,67 Thus, the possibility of SPAST
CNVs dysregulating SLC30A6 expression could potentially
inform the clinical observation of comorbid spastic para-
plegia and dementia.31 Neither RNA nor cells were available
from any subjects with combined SPG4 and dementia.
Seven CNVs have 30 breakpoints within the intergenic
regionbetweenSPASTandSLC30A6, andanadditional seven
have 30 breakpoints within the final exon of SPAST. The(E) Sequencing of PCR products in (A)–(C) demonstrates a variety of S
of which are present in the control individual (BAB 3099). Dots indic
scripts. Reading frame is unclear for transcripts with no dot. PCR pro
orientation, although only one orientation may be shown.
(F) SLC30A6 qPCR. In lymphoblastoid cell lines, overall level of expr
that of eight healthy controls (50th centile versus controls, empirical c
deviation.
The Amerformer group could affect SLC30A6 expression and all could
potentially form fusion transcripts. We investigated this
possibility experimentally usingRNA froman available non-
neuronal cell type (lymphoblastoid cell line) from one sub-
ject with a deletion encompassing the final exon of SPAST
(exon 17). A few low-abundance fusion transcripts were
present in a control individual, the significance of which is
unknown. However, abundant and additional fusion tran-
scriptswere present in the SPASTdeletion subject, indicating
that a deletion of only an exon of SPAST can affect gene
expression beyond the gene itself. The phenotypic conse-
quence of this, if any, requires additional investigation.
The expression level of SLC30A6 in lymphoblastoid cell
line RNA from this individual does not deviate signifi-
cantly from that of eight control lymphoblastoid cell lines.
Whether or not SLC30A6 expression is affected in this
individual in neurons is unknown.
Summary
Molecular characterization of novel SPAST CNV alleles
contributes to knowledge of pathogenic variants in this
gene and provides insights into the importance of partic-
ular exons for spastin function. Our data suggest that the
Alu-rich genomic architecture of SPAST predisposes to
CNVs in this gene, contributing appreciably to its muta-
bility and to SPG4 disease and potentially by a mechanism
other than homologous recombination. Furthermore,
these data allow the generation of hypotheses concerning
Alus as a genome-destabilizing entity. We provide evidence
that Alu-mediated rearrangements shape gene and genome
structure and that the CNVs that are generated affect both
SPAST and adjacent genes and extragenic regions. Thus,
such CNVs can affect gene expression beyond SPAST itself,
with potential phenotypic consequences.Supplemental Data
Supplemental Data include Supplemental Methods, six figures,
and three tables and can be found with this article online at
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